Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Obama Signs 21st Century Cures Act Into Law

XTALKS VITALS NEWS

Obama

The legislation will allocate $1.8 billion for a cancer research “moonshot” project, which has gained tremendous support from Vice President Joe Biden.

Share this!

December 15, 2016 | by Sarah Hand, M.Sc.

This week, President Barack Obama signed the 21st Century Cures Act – a bill that promises additional funding for cancer research and opioid addiction prevention – into law. The legislation will allocate $1.8 billion for a cancer research “moonshot” project, which has gained tremendous support from Vice President Joe Biden.

In all, the 21st Century Cures Act will provide $6.3 billion in additional funding towards multiple large-scale projects. Under the bill, states will be provided with $1 billion in funding over a two year period to use towards the prevention and treatment of opioids and other drug addictions.



The bill will also change the way the US Food and Drug Administration (FDA) approves new drugs, potentially allowing them to accept alternative data sources to expedite the approvals process. Patient advocacy groups like Public Citizen have been strongly opposed to this part of the act, arguing that it will weaken the drug approvals process.

“This bill remains a bad deal for patient safety, offering a small, temporary and non-guaranteed increase in public research funding at the expense of permanently weakening oversight by the Food and Drug Administration,” said a spokesperson from Public Citizen. The group is a non-profit organization that aims to represent all US citizens, and their interests, in Washington, D.C.

The signing event represented a rare moment of bipartisanship, with both parties offering their support for the bill. “I hope this bodes well for what will come next year - that we're back working together,” said Biden.

The 21st Century Cures Act was passed in the US House of Representatives earlier this month in a landslide 392 to 26 vote. As predicted, the bill easily passed through the Senate to allow it to be signed into law before the close of 2016.


Keywords: Cancer, FDA, Opioids


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
GSK Malaria Vaccine to be Pilot Tested in Three African Countries

April 25, 2017 - Ghana, Kenya and Malawi will become the first countries to test GlaxoSmithKline’s (GSK) malaria vaccine in 2018.

Featured In: Life Science News


AbbVie Posts Late-Stage Clinical Trial Results for Chronic Hepatitis C Drug

April 24, 2017 - Patients with a traditionally challenging to treat subtype of hepatitis C may soon have a new treatment option for the chronic infection.

Featured In: Clinical Trials News


Study: Few Cardiovascular Benefits of Aspirin Therapy for Patients with Peripheral Vascular Disease

April 24, 2017 - A new study conducted by researchers at the University of Florida has found that aspirin therapy may not provide sufficient cardiovascular benefits for patients with peripheral vascular disease.

Featured In: Clinical Trials News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

A Holistic Understanding of the Patient Journey Using Multiple Data Sources


Addressing the Challenges of Type II Diabetes Global Clinical Trials via Use of High Quality Laboratory Solutions


Clinical Trial Considerations in Cerebral Protection for TAVR Patients


Enabling Multi-Analyte Analysis of Lung Cancer FFPE Samples with 3D Biology™ Technology


Copyright © 2016-2017 Honeycomb Worldwide Inc.